Skip to content
DataLookout
Menu

GERAS-USNCT02951598

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 28 versions: 19 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Final enrollment: 1198 participants (planned 1400)
    • Study completion date changed from estimate of Apr 28, 2026 to Jan 30, 2021
  2. Minor Study completion date: Apr 28, 2023 to Apr 28, 2026v26
  3. Notable Phase: Not applicable to Not specifiedv25
  4. Minor Primary completion date changed from estimate of Jan 22, 2021 to Jan 30, 2021v24
  5. Minor Primary completion date: Oct 28, 2020 to Jan 22, 2021
    • Study completion date: Oct 28, 2020 to Apr 28, 2023
    v23
Show 14 earlier versionsHide 14 earlier versions
  1. Minor Study sites: 84 to 77v16
  2. Minor Primary completion date: Oct 2020 to Oct 28, 2020
    • Study completion date: Oct 2025 to Oct 28, 2020
    • Start date: Oct 2016 to Oct 29, 2016
    v15
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 91 to 84
    v14
  4. Minor Study sites: 86 to 91v13
  5. Minor Study sites revised (86)v12
  6. Minor Study sites: 79 to 86v11
  7. Minor Study sites: 81 to 79v10
  8. Minor Study sites: 79 to 81v9
  9. Minor Study sites: 78 to 79v8
  10. Minor Study sites: 74 to 78v7
  11. Minor Study sites: 46 to 74v6
  12. Minor Study sites revised (46)v5
  13. Minor Study sites: 47 to 46v4
  14. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 47
    v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Mean Economic Cost Associated with Amyloid Positive AD
Timeframe: Baseline through Study Completion (36 Months)

Secondary (12)

Healthcare Resource Use by AD Cohort
Mean Economic Cost by AD Cohort
Bath Assessment of Subjective Quality of Life in Dementia (BASQID)
Mini-Mental State Examination (MMSE)
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14)
Show 7 moreShow less
Neuropsychiatric Inventory (NPI)
Functional Activities Questionnaire (FAQ)
Cognitive Function Inventory (CFI)
Zarit Burden Interview (ZBI)
Percentage of Participants with a Change in Living Situation
Time to Transition Across Stages of AD
Desire to Institutionalize Scale (DTI)

Arms and interventions

MCI (Amyloid Positive)

Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.

Mild AD Dementia (Amyloid Positive)

Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.

MCI (Amyloid Negative)

Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.

Mild Dementia (Amyloid Negative)

Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.

Drugs: Florbetapir F 18 PET Scan

Sites

77 sites in 1 country